NASDAQ:DTIL Precision BioSciences (DTIL) Stock Price, News & Analysis → The Small Biotech with a BIG Cancer Solution (From Behind the Markets) (Ad) Free DTIL Stock Alerts $12.98 +0.23 (+1.80%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$11.59▼$13.3450-Day Range$10.80▼$18.5652-Week Range$8.25▼$28.44Volume324,403 shsAverage Volume217,027 shsMarket Capitalization$52.70 millionP/E RatioN/ADividend YieldN/APrice Target$75.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Precision BioSciences alerts: Email Address Precision BioSciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside477.8% Upside$75.00 Price TargetShort InterestHealthy4.94% of Float Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews Sentiment-0.23Based on 10 Articles This WeekInsider TradingSelling Shares$64,854 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($8.71) to ($6.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.22 out of 5 starsMedical Sector175th out of 939 stocksBiological Products, Except Diagnostic Industry22nd out of 156 stocks 3.5 Analyst's Opinion Consensus RatingPrecision BioSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $75.00, Precision BioSciences has a forecasted upside of 477.8% from its current price of $12.98.Amount of Analyst CoveragePrecision BioSciences has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.94% of the float of Precision BioSciences has been sold short.Short Interest Ratio / Days to CoverPrecision BioSciences has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Precision BioSciences has recently increased by 266.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPrecision BioSciences does not currently pay a dividend.Dividend GrowthPrecision BioSciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePrecision BioSciences has received a 72.17% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Precision BioSciences is -0.99. Previous Next 1.5 News and Social Media Coverage News SentimentPrecision BioSciences has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Precision BioSciences this week, compared to 3 articles on an average week.Search InterestOnly 10 people have searched for DTIL on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.MarketBeat Follows6 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Precision BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $64,854.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Precision BioSciences is held by insiders.Percentage Held by InstitutionsOnly 37.99% of the stock of Precision BioSciences is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Precision BioSciences are expected to grow in the coming year, from ($8.71) to ($6.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precision BioSciences is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precision BioSciences is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecision BioSciences has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Precision BioSciences Stock (NASDAQ:DTIL)Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Read More DTIL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DTIL Stock News HeadlinesMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Precision BioSciences as Milestones in Gene Editing Technology LoomMarch 27, 2024 | investorplace.comDTIL Stock Earnings: Precision BioSciences Misses EPS, Misses Revenue for Q4 2023March 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 27, 2024 | markets.businessinsider.comPrecision BioSciences Inc Q4 Loss decreases, but misses estimatesMarch 27, 2024 | businesswire.comPrecision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business UpdateMarch 26, 2024 | benzinga.comEarnings Preview: Precision BioSciencesMarch 26, 2024 | msn.comPrecision BioSciences Q4 Earnings PreviewMarch 25, 2024 | americanbankingnews.comPrecision BioSciences (DTIL) Set to Announce Earnings on WednesdayMarch 28, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 20, 2024 | businesswire.comPrecision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024March 19, 2024 | baystreet.caPrecision BioSciences Flat on New Product DevelopmentMarch 19, 2024 | businesswire.comPrecision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial MyopathyMarch 18, 2024 | finance.yahoo.comDNAnexus to Showcase the Power of High-Value Multi-Omics Data at the Precision Medicine in IBD SummitMarch 15, 2024 | yahoo.comFender teams up with Fornite to bring its Stratocaster and Precision Bass to the digital realmMarch 14, 2024 | bizjournals.comMachining company Thomas Precision sells vacant Union County facilityMarch 12, 2024 | msn.comThe Anova Precision Cooker Nano sous vide machine drops to a record low of $60March 7, 2024 | finance.yahoo.comPrecision BioSciences, Inc. (PBS0.F)March 6, 2024 | businesswire.comPrecision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC DeficiencyMarch 4, 2024 | bizjournals.comDurham gene editing firm raising $40M for Hepatitis B treatmentMarch 2, 2024 | investing.comPrecision BioSciences announces public stock offeringMarch 1, 2024 | marketwatch.comPrecision BioSciences Shares Slide Premarket After Stock OfferingMarch 1, 2024 | msn.comCardiff Oncology, DermTech, Precision Biosciences among healthcare moversMarch 1, 2024 | markets.businessinsider.comPrecision BioSciences Sinks 30%; Sets $40 Mln Stock OfferingMarch 1, 2024 | markets.businessinsider.comPrecision BioSciences Slips Over 16% In Pre-market; Prices Offering Of $40 Mln Of SharesMarch 1, 2024 | businesswire.comPrecision BioSciences Announces $40.0 Million Offering of Common Stock and WarrantsFebruary 29, 2024 | businesswire.comPrecision BioSciences Announces Proposed Public Offering of Common Stock and WarrantsFebruary 24, 2024 | msn.comPrecision BioSciences (DTIL) Price Target Increased by 2900.00% to 80.33See More Headlines Receive DTIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:DTIL CUSIPN/A CIK1357874 Webwww.precisionbiosciences.com Phone(919) 314-5512FaxN/AEmployees115Year FoundedN/APrice Target and Rating Average Stock Price Target$75.00 High Stock Price Target$90.00 Low Stock Price Target$60.00 Potential Upside/Downside+477.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($19.8198) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-111,640,000.00 Net Margins-140.60% Pretax Margin-164.10% Return on Equity-189.47% Return on Assets-39.33% Debt Debt-to-Equity RatioN/A Current Ratio2.88 Quick Ratio2.88 Sales & Book Value Annual Sales$25.10 million Price / Sales2.10 Cash FlowN/A Price / Cash FlowN/A Book Value$16.36 per share Price / Book0.79Miscellaneous Outstanding Shares4,060,000Free Float3,853,000Market Cap$52.70 million OptionableOptionable Beta1.56 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Michael Amoroso (Age 45)President, CEO & Director Comp: $979.04kMr. John Alexander Kelly R.Ph. (Age 57)CFO & Principal Accounting Officer Comp: $623.58kMr. Dario Scimeca (Age 48)General Counsel & Secretary Comp: $576.43kDr. Jefferson J. Smith Ph.D. (Age 51)Co-Founder & Chief Research Officer Mei BurrisDirector of Investor Relations & FinanceMr. Bruce StevensVice President of Quality & ComplianceMaurissa MessierSenior Director of Corporate CommunicationsMs. Juli BlancheChief People OfficerMr. Garrett GincleyHead of ManufacturingDr. Alan F. List M.D. (Age 69)Chief Medical Officer More ExecutivesKey CompetitorsProtara TherapeuticsNASDAQ:TARAQuince TherapeuticsNASDAQ:QNCXEstrella ImmunopharmaNASDAQ:ESLAAchilles TherapeuticsNASDAQ:ACHLEntera BioNASDAQ:ENTXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 61,700 shares on 3/11/2024Ownership: 117.113%Goldman Sachs Group Inc.Bought 19,636 shares on 3/1/2024Ownership: 12.160%Vanguard Group Inc.Bought 61,700 shares on 2/15/2024Ownership: 3.900%Blue Owl Capital Holdings LPBought 606,629 shares on 2/15/2024Ownership: 0.498%Barclays PLCBought 20,316 shares on 2/15/2024Ownership: 0.176%View All Insider TransactionsView All Institutional Transactions DTIL Stock Analysis - Frequently Asked Questions Should I buy or sell Precision BioSciences stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DTIL shares. View DTIL analyst ratings or view top-rated stocks. What is Precision BioSciences' stock price target for 2024? 2 analysts have issued 1 year price objectives for Precision BioSciences' shares. Their DTIL share price targets range from $60.00 to $90.00. On average, they predict the company's stock price to reach $75.00 in the next year. This suggests a possible upside of 477.8% from the stock's current price. View analysts price targets for DTIL or view top-rated stocks among Wall Street analysts. How have DTIL shares performed in 2024? Precision BioSciences' stock was trading at $10.95 at the start of the year. Since then, DTIL stock has increased by 18.5% and is now trading at $12.98. View the best growth stocks for 2024 here. How were Precision BioSciences' earnings last quarter? Precision BioSciences, Inc. (NASDAQ:DTIL) issued its earnings results on Wednesday, November, 10th. The company reported ($5.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($17.70) by $12.00. The company earned $24.04 million during the quarter, compared to analysts' expectations of $8.54 million. Precision BioSciences had a negative trailing twelve-month return on equity of 189.47% and a negative net margin of 140.60%. During the same quarter last year, the business posted ($15.00) EPS. What ETF holds Precision BioSciences' stock? Kelly CRISPR & Gene Editing Technology ETF holds 133,661 shares of DTIL stock, representing 2.96% of its portfolio. When did Precision BioSciences' stock split? Precision BioSciences shares reverse split on the morning of Wednesday, February 14th 2024. The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What is Matt Kane's approval rating as Precision BioSciences' CEO? 12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Precision BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA). When did Precision BioSciences IPO? Precision BioSciences (DTIL) raised $126 million in an initial public offering (IPO) on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO. Who are Precision BioSciences' major shareholders? Precision BioSciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Capital World Investors (4.20%), Vanguard Group Inc. (3.90%), Vanguard Group Inc. (117.11%), Blue Owl Capital Holdings LP (0.50%), Goldman Sachs Group Inc. (12.16%) and Corient Private Wealth LLC (0.19%). Insiders that own company stock include Alan List, Dario Scimeca, David S Thomson, David S Thomson, Derek Jantz, John Alexander Kelly, Matthew R Kane, Matthew R Kane, Michael Amoroso and Vince Craig Hopkin. View institutional ownership trends. How do I buy shares of Precision BioSciences? Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DTIL) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.